THURSDAY, Feb. 11, 2021 (HealthDay Information) — People with chubby or weight problems receiving once-weekly subcutaneous semaglutide plus life-style intervention achieved sustained, clinically related reductions in physique weight, in accordance with a research revealed on-line Feb. 10 within the New England Journal of Medication.
John P. H. Wilding, D.M., from the College of Liverpool in the UK, and colleagues enrolled 1,961 adults with a physique mass index of 30 or larger who didn’t have diabetes and randomly assigned them to 68 weeks of both once-weekly subcutaneous semaglutide or placebo plus life-style intervention in a 2:1 ratio.
The researchers discovered that the imply change in physique weight from baseline to week 68 was −14.9 and −2.4 p.c within the semaglutide and placebo teams, respectively, for an estimated remedy distinction of −12.4 p.c. At week 68, in contrast with the placebo group, extra individuals within the semaglutide group achieved weight lack of 5 p.c or extra (86.4 versus 31.5 p.c), 10 p.c or extra (69.1 versus 12.0 p.c), and 15 p.c or extra (50.5 versus 4.9 p.c). With respect to cardiometabolic threat components, individuals who obtained semaglutide had larger enchancment than these receiving placebo. The commonest opposed occasions with semaglutide have been nausea and diarrhea, which have been sometimes transient, have been delicate to average in severity, and decreased with time.
“The STEP 1 trial (like its title) is an effective starting,” write the authors of an accompanying editorial. “Nevertheless, as famous by the authors, there are issues, together with opposed occasions.”
The research was funded by Novo Nordisk, the producer of semaglutide.